In a scathing and precedent-setting ruling against Discovery Health Medical Scheme, the industry regulator has opened the door for consumers to force the industry to pay for treatment not available in state hospitals.

The Council for Medical Schemes’s (CMS’s) ruling follows a case by an eye-disease glaucoma patient, who took the scheme, which is administered by financial services group Discovery’s health insurance arm, on after it refused to pay for an implant of a medicated device called a Xen stent to lower eye pressure as recommended by a specialist...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now